Yale Launches Comprehensive DNA Sequencing Project, With Aim of Predicting, Preventing, and Treating Gene-related Diseases
Generations, a collaboration between Yale School of Medicine and Yale New Haven Health System, is one of the largest DNA sequencing projects of its kind in the United States.
Yale-developed Scorecard Promotes Better Clinical Trial Data Sharing
A tool developed by researchers at Yale, Stanford, and Bioethics International can promote greater sharing of clinical trial data by pharmaceutical companies. While nearly one-third of the companies that the researchers assessed met standards for sharing data, others could be more transparent to the benefit of science and the public, the researchers said.
Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Yale Study Finds Link Between Medicaid Expansion and Equity in Cancer Care
Racial disparities in timely cancer treatment disappeared in states that expanded Medicaid under the Affordable Care Act (ACA), according to an analysis of over 30,000 health records led by researchers at Yale Cancer Center. The findings were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.
Women’s Health Research at Yale funds studies on pain relief, cannabis, and genetic origins of sex differences in disease
Women’s Health Research at Yale (WHRY) today announced funding for first-of-their-kind studies on pain relief, cannabis, and the genetic basis of sex differences across a broad range of ailments, including Alzheimer’s disease and heart disease.
Yale launches new policy lab to elevate mental health and disrupt poverty
Children born in poverty often experience negative consequences over the course of their lives and pass on the same disadvantages to their own children. Now a new initiative introduced at Yale aims to break the cycle of poverty by focusing first on the mental health needs of parenting and pregnant women.
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
Yonkers, Forray Co-PIs on New Grant to Study Medication Delivery for Pregnant Women with Opioid Use Disorders
Kimberly Yonkers, MD, Professor of Psychiatry, of Epidemiology (Chronic Diseases) and of Obstetrics, Gynecology, and Reproductive Services, and Ariadna Forray, MD, Associate Professor of Psychiatry, are co-principal investigators on a new $5.5 million grant to study models to improve delivery of office-based medication treatment for pregnant women with opioid use disorder in prenatal clinics.
National Cancer Center Partnership Expected to Advance Cancer Research at YSPH, Yale
A new partnership with the National Cancer Center of China will provide opportunities for collaborative research, clinical trials and workforce training at the Yale School of Public Health, Yale Cancer Center and Yale Institute for Global Health.
A Better Way to Classify Young Women’s Heart Attacks
A new study, sponsored by Women’s Health Research at Yale, shows how a sex-specific classification system can define and group types of heart attacks that are more common for women. In doing so, the researchers have produced a more accurate guide to treatment and prognosis.
Low mobility predicts hospital readmission in older heart attack patients
Close to 20% of elderly adults who have suffered a heart attack will be readmitted to the hospital within 30 days. Performance on a simple mobility test is the best predictor of whether an elderly heart attack patient will be readmitted, a Yale-led study reports.
High-dose Vitamin D Shows Benefit in Patients with Advanced Colorectal Cancer
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease. The findings, by researchers from Yale Cancer Center and Dana-Farber Cancer Institute, are published in the Journal of the American Medical Association (JAMA).
Text Messages Show Promise as Next Step for Improving Heart Health in China
Motivational text messages are a well-liked, feasible new way to provide additional support to Chinese patients with heart disease, reports a preliminary study by researchers at Yale and in China. However, the study did not prove that these targeted text messages led to an improvement in blood pressure control amongst the recipients, the intended outcome.
Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Since 1990s, Heart Attacks Have Become Less Deadly and Frequent for Americans
Heart attack prevention and outcomes have dramatically improved for American adults in the past two decades, according to a Yale study in JAMA Network Open. Compared to the mid-1990s, Americans today are less likely to have heart attacks and also less likely to die from them, said the researchers.
Yale Cancer Center Researchers Find Treatment for Rare Blood Cancer Saves Lives, but Is Underused
Clinical trials have pointed a way toward treatment of essential thrombocythemia (ET), a rare, incurable cancer caused by massive overproduction of blood platelets. But the use and benefit of the therapy, hydroxyurea (HU), which suppresses formation of blood cells, had never been studied in a “real world” setting. Researchers at Yale Cancer Center now report that HU significantly reduces risk of thrombotic events including venous thrombosis, strokes, and heart attacks and lowers death rates in patients who use it.